Elan Small
University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elan Small as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06450899 · Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain SicknessUniversity of Colorado, Denver · completed · Acute Mountain Sickness · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:20 UTC. The ranking covers the 200 most relevant of 176 PubMed records, and a shared surname and initials can bring in a namesake. All 176 on PubMed
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med · 20104,465 citationsRCR 103.9
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med · 20043,025 citationsRCR 65.3
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- 1,126 citationsRCR 35.2
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.N Engl J Med · 20181,042 citationsRCR 38.8
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.J Clin Oncol · 2006897 citationsRCR 17.9
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.J Clin Oncol · 2008731 citationsRCR 15.6
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol · 2018698 citationsRCR 22.3
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.JAMA Oncol · 2019684 citationsRCR 31.4
- 645 citationsRCR 13.6